Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Net Margin came in at 231.74% in Q2 2026, down 7766.0% on a YoY basis from 3.02% in Q2 2025, and up 45.36% quarter-over-quarter from 424.09% in Q1 2026.
Powered by 
Analysis
Ginkgo Bioworks Holdings (DNA) Net Margin (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has reported Net Margin for 7 consecutive years, with 231.74% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, Net Margin fell 7766.0% year-over-year to 231.74%; the trailing twelve-month figure through Jun 2026 stood at 259.96% (down 11005.0% YoY), and the FY2025 full-year result was 183.81%, up 5713.0% from the prior year.
- Net Margin climbed to 231.74% in Q2 2026 per DNA's latest filing, from 424.09% in the prior quarter.
- Across five years, Net Margin topped out at 63.34% in Q3 2024 and bottomed at 1009.26% in Q3 2022.
- Historically, Net Margin has averaged 318.45% across 5 years, with a median of 243.52% in 2024.
- The widest YoY moves for Net Margin: up 90475 bps in 2022, down 87732 bps in 2022.
- Over 5 years, Net Margin stood at 176.1% in 2022, then soared by 51 bps to 87.09% in 2023, then tumbled by 182 bps to 245.25% in 2024, then advanced by 1 bps to 241.8% in 2025, then grew by 4 bps to 231.74% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 231.74%, 424.09%, and 241.8% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Iqvia Holdings | 44.06 Bn | 42.11 Bn | 1.44 Bn | 5.52% |
| 2 | Medpace Holdings | 16.50 Bn | 16.00 Bn | 201.64 Mn | 17.16% |
| 3 | Charles River Laboratories International | 13.77 Bn | 13.62 Bn | 452.07 Mn | -0.08% |
| 4 | Icon | 12.62 Bn | 11.69 Bn | 479.29 Mn | 9.61% |
| 5 | Fortrea Holdings | 1.68 Bn | 1.51 Bn | 139.20 Mn | -1.95% |
| 6 | Evotec SE | 661.34 Mn | 235.46 Mn | - | - |
| 7 | Ginkgo Bioworks Holdings | 442.79 Mn | 358.26 Mn | 18.44 Mn | -231.74% |
| 8 | Champions Oncology | 72.49 Mn | 72.62 Mn | 7.03 Mn | -4.82% |
| 9 | MindWalk Holdings | 61.66 Mn | 53.38 Mn | 1.82 Mn | -83.13% |
| 10 | VivoSim Labs | 1.47 Mn | 1.47 Mn | - | -15,211.11% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -231.74% |
| Mar 31, 2026 | -424.09% |
| Dec 31, 2025 | -241.80% |
| Sep 30, 2025 | -207.93% |
| Jun 30, 2025 | -154.09% |
| Mar 31, 2025 | -237.92% |
| Dec 31, 2024 | -245.25% |
| Sep 30, 2024 | -63.34% |
| Jun 30, 2024 | -386.40% |
| Mar 31, 2024 | -437.25% |
| Dec 31, 2023 | -87.09% |
| Sep 30, 2023 | -546.44% |
| Jun 30, 2023 | -215.12% |
| Mar 31, 2023 | -253.98% |
| Dec 31, 2022 | -176.10% |
| Sep 30, 2022 | -1,009.26% |
| Jun 30, 2022 | -463.68% |
| Mar 31, 2022 | -350.65% |
| Dec 31, 2021 | -1,080.85% |
| Sep 30, 2021 | -131.95% |